Eosinophilic granulomatosis with polyangiitis
MONDO:0015943Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a systemic vasculitis of small-to medium vessels, characterized by asthma, transient pulmonary infiltrates, and hypereosinophilia.
Also known as: CSS, Churg Strauss Syndrome, Churg Strauss syndrome, Churg-Strauss syndrome, Churg-Strauss vasculitis, EGPA, allergic angiitides, allergic angiitides, granulomatous
38 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug could simplify treatment for rare EGPA disease
Disease control OngoingThis study tests whether a newer drug, benralizumab, works as well as the current standard, mepolizumab, for people with a rare disease called EGPA that inflames blood vessels. About 140 adults with active EGPA will receive either drug for a year, along with their usual steroids.…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to tame rare inflammatory disease
Disease control OngoingThis phase 3 trial tests whether a new drug, depemokimab, works as well as the current treatment mepolizumab for adults with a rare disease called EGPA, which causes inflammation of blood vessels. The study involves 163 participants and aims to see if depemokimab can help patient…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for rare disease: can NS-229 help patients reduce steroids?
Disease control OngoingThis study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid d…
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug shows promise for rare blood vessel disease
Disease control OngoingThis study tests a drug called tezepelumab in 42 adults with EGPA, a rare disease that causes inflammation in blood vessels and can damage organs. The goal is to see if the drug helps patients reach remission, meaning no active disease and low steroid use. Participants receive ei…
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug may tame rare vasculitis and cut steroid dependence
Disease control OngoingThis study tests whether a drug called mepolizumab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) reach remission better than standard treatments. About 100 adults with active EGPA will receive either mepolizumab or usual care, and…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Proteomics may unlock key clues to mepolizumab success in rare lung disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC